Abbott Laboratories Company Profile (NYSE:ABT)

About Abbott Laboratories

Abbott Laboratories logoAbbott Laboratories (Abbott) is engaged in the discovery, development, manufacture and sale of a line of healthcare products. The Company operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks, commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary, endovascular, structural heart, vessel closure and other medical device products. Its Established Pharmaceutical Products segment's therapeutic area portfolio of products includes gastroenterology products, women's health products, and respiratory drugs and vaccines.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Appliances & Equipment
  • Sub-Industry: Health Care Equipment
  • Exchange: NYSE
  • Symbol: ABT
  • CUSIP: 00282410
Key Metrics:
  • Previous Close: $42.22
  • 50 Day Moving Average: $43.02
  • 200 Day Moving Average: $41.20
  • 52-Week Range: $1,469,995,000.00 - $36.00
  • Trailing P/E Ratio: 27.85
  • Foreward P/E Ratio: 17.01
  • P/E Growth: 2.00
  • Market Cap: $62.02B
  • Outstanding Shares: 1,469,995,000
  • Beta: 0.82
  • Net Margins: 11.08%
  • Return on Equity: 15.11%
  • Return on Assets: 7.83%
  • Debt-to-Equity Ratio: 0.29%
  • Current Ratio: 1.50%
  • Quick Ratio: 1.17%
Additional Links:
Companies Related to Abbott Laboratories:

Analyst Ratings

Consensus Ratings for Abbott Laboratories (NYSE:ABT) (?)
Ratings Breakdown: 6 Hold Ratings, 15 Buy Ratings
Consensus Rating:Buy (Score: 2.71)
Consensus Price Target: $46.79 (10.89% upside)

Analysts' Ratings History for Abbott Laboratories (NYSE:ABT)
DateFirmActionRatingPrice TargetDetails
9/19/2016Bank of America Corp.Reiterated RatingBuyView Rating Details
9/19/2016Royal Bank Of CanadaReiterated RatingOutperform$48.00View Rating Details
9/13/2016Jefferies GroupLower Price TargetBuy$52.00 -> $48.00View Rating Details
8/10/2016BTIG ResearchReiterated RatingBuy$45.00View Rating Details
8/9/2016Deutsche Bank AGReiterated RatingBuyView Rating Details
7/28/2016ArgusReiterated RatingBuy$55.00View Rating Details
7/21/2016Barclays PLCBoost Price TargetOverweight$48.00 -> $50.00View Rating Details
6/21/2016Edward JonesUpgradeHold -> BuyView Rating Details
6/8/2016Credit Suisse Group AGReiterated RatingBuyView Rating Details
5/12/2016Wells Fargo & Co.Reiterated RatingBuyView Rating Details
5/2/2016BMO Capital MarketsReiterated RatingBuyView Rating Details
4/30/2016S&P Equity ResearchReiterated RatingHoldView Rating Details
4/30/2016GabelliReiterated RatingBuyView Rating Details
4/28/2016Piper Jaffray Cos.DowngradeOverweight -> NeutralView Rating Details
4/21/2016Cowen and CompanyReiterated RatingNeutral -> Buy$44.00 -> $48.00View Rating Details
4/14/2016First GlobalDowngradeOutperform -> MarketperformView Rating Details
3/28/2016Stifel NicolausBoost Price TargetBuy$42.00 -> $47.00View Rating Details
3/28/2016Leerink SwannBoost Price TargetMarket Perform$37.00 -> $40.00View Rating Details
1/29/2016Raymond James Financial Inc.Lower Price TargetOutperform$46.00 -> $42.00View Rating Details
1/29/2016Goldman Sachs Group Inc.Lower Price TargetNeutral$44.00 -> $40.00View Rating Details
1/29/2016William BlairDowngradeOutperform -> Market PerformView Rating Details
1/4/2016Morgan StanleyDowngradeOverweight -> Equal Weight$50.00View Rating Details
5/27/2015Evercore Partners Inc.Initiated CoverageBuy$54.00View Rating Details
5/26/2015Evercore ISIInitiated CoverageBuy$54.00View Rating Details
4/23/2015JPMorgan Chase & Co.Boost Price TargetNeutral$46.00 -> $48.00View Rating Details
(Data available from 9/25/2014 forward)


Earnings History for Abbott Laboratories (NYSE:ABT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/19/2016ListenView Earnings Details
7/20/2016Q216$0.53$0.55$5.24 billion$5.30 billionViewListenView Earnings Details
4/20/2016Q116$0.39$0.41$4.77 billion$4.90 billionViewListenView Earnings Details
1/28/2016Q415$0.61$0.62$5.31 billion$5.20 billionViewListenView Earnings Details
10/21/2015Q315$0.53$0.54$5.16 billion$5.15 billionViewListenView Earnings Details
7/22/2015Q215$0.50$0.52$5.15 billion$5.20 billionViewListenView Earnings Details
4/22/2015Q115$0.42$0.47$4.85 billion$4.90 billionViewListenView Earnings Details
1/29/2015Q414$0.69$0.71$5.48 billion$5.36 billionViewListenView Earnings Details
10/22/2014Q314$0.59$0.62$5.62 billion$5.10 billionViewListenView Earnings Details
7/16/2014Q214$0.51$0.54$5.53 billion$5.55 billionViewListenView Earnings Details
4/16/2014Q114$0.36$0.41$5.29 billion$5.24 billionViewListenView Earnings Details
1/22/2014Q413$0.58$0.58$5.72 billion$5.66 billionViewListenView Earnings Details
10/16/2013Q313$0.52$0.55$5.46 billion$5.37 billionViewListenView Earnings Details
7/17/2013Q2 2013$0.44$0.46$5.53 billion$5.45 billionViewListenView Earnings Details
4/17/2013Q1 2013$0.41$0.42$5.42 billion$5.38 billionViewListenView Earnings Details
1/23/2013Q4 2012$1.50$1.51$10.58 billion$10.80 billionViewListenView Earnings Details
10/17/2012$1.28$1.30ViewN/AView Earnings Details
7/18/2012$1.22$1.23ViewN/AView Earnings Details
4/18/2012$1.00$1.03ViewN/AView Earnings Details
1/25/2012$1.44$1.45ViewN/AView Earnings Details
10/19/2011$1.17$1.18ViewN/AView Earnings Details
7/20/2011$1.12$1.12ViewN/AView Earnings Details
4/20/2011$0.90$0.91ViewN/AView Earnings Details
1/26/2011$1.29$1.30ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Abbott Laboratories (NYSE:ABT)
Current Year EPS Consensus Estimate: $2.2 EPS
Next Year EPS Consensus Estimate: $2.48 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163$0.39$0.40$0.39
Q2 20165$0.51$0.54$0.53
Q3 20163$0.58$0.60$0.59
Q4 20162$0.66$0.67$0.67
Q1 20173$0.44$0.51$0.47
Q2 20172$0.60$0.62$0.61
Q3 20172$0.63$0.63$0.63
Q4 20172$0.69$0.71$0.70
Q1 20181$0.51$0.51$0.51
(Data provided by Zacks Investment Research)


Current Dividend Information for Abbott Laboratories (NYSE:ABT)
Annual Dividend:$1.04
Dividend Yield:2.47%
Dividend Growth:-21.80% (3 Year Average)
Payout Ratio:68.87% (Based on Trailing 12 Months of Earnings)
47.27% (Based on Current Year Consensus EPS Estimate)
41.94% (Based on Next Year Consensus EPS Estimate)
Track Record:43 Years of Consecutive Dividend Growth

Dividend History for Abbott Laboratories (NYSE:ABT)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Abbott Laboratories (NYSE:ABT)
Insider Ownership Percentage: 0.26%
Institutional Ownership Percentage: 73.03%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/28/2016Stephen R FussellInsiderSell41,500$45.00$1,867,500.00View SEC Filing  
7/26/2016Michael J WarmuthInsiderSell26,800$43.49$1,165,532.00View SEC Filing  
7/25/2016Miles D WhiteChairmanBuy242,547$43.18$10,473,179.46View SEC Filing  
7/25/2016Robert E FunckVPSell26,800$43.08$1,154,544.00View SEC Filing  
6/28/2016Hubert L AllenEVPSell3,400$37.14$126,276.00View SEC Filing  
6/15/2016Jared WatkinSVPSell552$37.63$20,771.76View SEC Filing  
6/1/2016Brian B YoorCFOSell565$39.49$22,311.85View SEC Filing  
4/28/2016Deepak S NathSVPSell53$41.31$2,189.43View SEC Filing  
3/31/2016Jaime ContrerasSVPSell462$41.78$19,302.36View SEC Filing  
2/29/2016Brian B YoorCFOSell865$39.12$33,838.80View SEC Filing  
2/29/2016Deepak S NathSVPSell793$39.27$31,141.11View SEC Filing  
2/29/2016Robert B FordEVPSell1,706$39.28$67,011.68View SEC Filing  
2/29/2016Robert E FunckVPSell1,333$39.30$52,386.90View SEC Filing  
2/22/2016Jared WatkinSVPSell554$39.09$21,655.86View SEC Filing  
2/16/2016Deepak S. NathSVPSell171$37.13$6,349.23View SEC Filing  
12/16/2015Miles D. WhiteCEOSell438,000$46.00$20,148,000.00View SEC Filing  
8/18/2015Stephen R. FussellEVPSell13,096$50.46$660,824.16View SEC Filing  
4/27/2015Heather L MasonEVPSell13,500$47.45$640,575.00View SEC Filing  
4/27/2015Roger BirdSVPSell28,548$47.57$1,358,028.36View SEC Filing  
3/26/2015J. Scott WhiteSVPSell12,483$46.68$582,706.44View SEC Filing  
3/2/2015Jaime ContrerasSVPSell9,209$47.34$435,954.06View SEC Filing  
2/4/2015John M CapekEVPSell34,292$45.66$1,565,772.72View SEC Filing  
11/25/2014Jaime ContrerasSVPSell51,600$44.07$2,274,012.00View SEC Filing  
10/29/2014Miles D WhiteCEOSell440,800$42.52$18,742,816.00View SEC Filing  
3/3/2014John LandgrafEVPSell17,293$39.38$680,998.34View SEC Filing  
3/3/2014Katherine DoyleSVPSell6,639$39.01$258,987.39View SEC Filing  
3/3/2014Robert FunckVPSell1,413$38.97$55,064.61View SEC Filing  
2/18/2014John LandgrafEVPSell1,583$39.10$61,895.30View SEC Filing  
1/29/2014Michael WarmuthEVPSell11,430$36.21$413,880.30View SEC Filing  
12/6/2013Jean-Yves PaveeSVPSell5,855$37.46$219,328.30View SEC Filing  
11/7/2013Stephen FussellEVPSell10,466$37.59$393,416.94View SEC Filing  
10/30/2013Jaime ContrerasSVPSell25,368$36.85$934,810.80View SEC Filing  
6/7/2013Heather L MasonSVPSell12,000$37.01$444,120.00View SEC Filing  
2/1/2013William A OsbornDirectorBuy10,000$33.86$338,600.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Abbott Laboratories (NYSE:ABT)
News IconMedical Appliances & Equipment: Abbott Laboratories (NYSE:ABT) Position of the day (NYSE:ABT) - September 24 at 3:15 PM
News IconGalena Biopharma Inc (NASDAQ:GALE) & Abbott Laboratories (NYSE:ABT) Watch List - Money News (NYSE:ABT) - September 22 at 3:15 PM logoInteresting ABT Put And Call Options For November 4th (NYSE:ABT) - September 22 at 12:25 PM
News IconHC Stocks Judgment! Navidea Biopharmaceuticals Inc (NAVB), Abbott Laboratories (NYSE:ABT) - share market updates (press release) (NYSE:ABT) - September 22 at 8:11 AM logoMalnutrition Adds $15.5 Billion Annually to Direct U.S. Medical Costs (NYSE:ABT) - September 21 at 3:22 PM logoDisease-related malnutrition costs U.S. $15.5 bln annually - study (NYSE:ABT) - September 21 at 3:22 PM logoAbbott Laboratories : to Delist from London Stock Exchange (NYSE:ABT) - September 21 at 11:13 AM logoAbbott Labs Plans To Cancel Listing On LSE (NYSE:ABT) - September 21 at 11:13 AM logoAbbott Hosts Conference Call for Third-Quarter Earnings (NYSE:ABT) - September 21 at 11:13 AM logoThe Zacks Analyst Blog Highlights: Abbott Labs, Comcast, Goldman Sachs, Microsoft and Philip Morris (NYSE:ABT) - September 21 at 11:13 AM logoBristol-Myers Opdivo's Regulatory Application Validated in EU (NYSE:ABT) - September 21 at 11:13 AM logoFueling Performance with Fat: EAS® Launches First Ketogenic Meal Replacement For Athletes (NYSE:ABT) - September 20 at 3:15 PM logo[$$] Abbott's Deal With JNJ Is Good Strategy (NYSE:ABT) - September 20 at 3:15 PM logoJohnson & Johnson's Smart (Yet Surprising) Acquisition (NYSE:ABT) - September 20 at 3:15 PM logoTop Research Reports for Goldman Sachs, Comcast & Abbott Labs (NYSE:ABT) - September 20 at 3:15 PM
News IconMaking Sense of Abbott’s Sale Of Its Optics Business (NYSE:ABT) - September 19 at 4:05 PM logoAbbott Laboratories - Reducing Leverage And Increasing Focus Following Vision Care Divestment (NYSE:ABT) - September 19 at 4:05 PM logoAbbott Laboratories : Nippon Life Insurance Co Lowers stake in Abbott Laboratories (ABT) (NYSE:ABT) - September 19 at 4:05 PM
News IconAbbott Laboratories (ABT) Dividend Stock Analysis (NYSE:ABT) - September 19 at 4:05 PM logoCredit Suisse Can Clearly See Why Johnson & Johnson Acquired Abbott's Optics Division (NYSE:ABT) - September 19 at 4:05 PM logoAbbott's Eye Deal Isn't About Alere (NYSE:ABT) - September 19 at 4:05 PM logoUS stocks mostly higher as banks rise before Fed meeting (NYSE:ABT) - September 19 at 4:05 PM
News IconStock under Review - Abbott Laboratories's (ABT) - Hot Stocks Point (NYSE:ABT) - September 19 at 8:02 AM logoAbbott Laboratories - Reducing Leverage And Increasing Focus ... - Seeking Alpha (NYSE:ABT) - September 19 at 8:02 AM logoAP Top Extended Financial Headlines at 11:47 a.m. EDT (NYSE:ABT) - September 17 at 3:15 PM logoThe 3 Best Long-Term Dividend Stocks to Buy Now (NYSE:ABT) - September 17 at 8:03 AM logo[$$] J&J to Buy Abbott’s Eye-Surgery Equipment Unit for $4.325 billion (NYSE:ABT) - September 17 at 8:03 AM logoUPDATE 3-Abbott to sell its eye care business to J&J for about $4.33 bln (NYSE:ABT) - September 16 at 6:49 PM logoJohnson & Johnson (JNJ) Stock Lower, Buys Abbott Laboratories' Medical Optics Unit for $4.3 Billion - (NYSE:ABT) - September 16 at 4:27 PM
News IconStocks Getting Investors Vote of Confidence: Abbott Laboratories (NYSE:ABT), Zimmer Biomet Holdings, Inc. (NYSE:ZBH) - Street Wise Report (press release) (blog) (NYSE:ABT) - September 16 at 3:17 PM
News Icon$PFE & $ABT - Pfizer Inc. (NYSE:PFE) & Abbott Laboratories (NYSE:ABT) Stocks in the Spotlight - Money News (NYSE:ABT) - September 16 at 3:17 PM
News IconHC Stocks Momentum! Baxter International Inc (BAX), Abbott Laboratories (NYSE:ABT) - share market updates (press release) (NYSE:ABT) - September 16 at 3:17 PM logoJ&J Nears Deal to Buy Abbott's Eye-Surgery Equipment Unit - Wall Street Journal (NYSE:ABT) - September 16 at 3:17 PM
News IconAbbott Laboratories (NYSE:ABT) To Report September 2016 Results - The Voice Registrar (NYSE:ABT) - September 16 at 3:17 PM logo[$$] J&J Nears Deal to Buy Abbott's Eye-Surgery Unit (NYSE:ABT) - September 16 at 3:17 PM logoAbbott in talks to sell its eye-surgery business to J&J - WSJ (NYSE:ABT) - September 16 at 3:17 PM logoAbbott to Sell Abbott Medical Optics to Johnson & Johnson for $4.325 Billion (NYSE:ABT) - September 16 at 3:17 PM logoJohnson & Johnson to buy Abbott Labs medical optics subsidiary for $4.3bln (NYSE:ABT) - September 16 at 3:17 PM logoJ&J to buy Abbott's eye care business for about $4.33 bln (NYSE:ABT) - September 16 at 3:17 PM
News IconFlossbach Von Storch Ag Increased Abbott Laboratories (NYSE:ABT) by $215.71 Million as Shares Declined - Chester News (NYSE:ABT) - September 15 at 8:27 PM logoAbbott Laboratories declares $0.26 dividend (NYSE:ABT) - September 15 at 12:06 PM logoAbbott Declares 371st Consecutive Quarterly Dividend (NYSE:ABT) - September 15 at 12:06 PM
News IconLeverage To Be A Challenge For Abbott, Once Deals Close: Part 1 (NYSE:ABT) - September 14 at 8:33 PM logoCan Abbott Labs Find a Cure for Its Ailing Shares? - (NYSE:ABT) - September 14 at 3:15 PM
News IconAbbott Laboratories (NYSE:ABT) from Medical Appliances & Equipment – Todays Top Gains (NYSE:ABT) - September 12 at 3:15 PM logoReads For The Weed-Kend: Marijuana Roadside Testing, Pregnancy And Depression (NYSE:ABT) - September 12 at 8:02 AM logo3 Great Dividend Stocks in the Bargain Bin for Retirees (NYSE:ABT) - September 11 at 8:02 AM
News IconHC Stocks Reports= Abbott Laboratories (ABT), Johnson & Johnson (NYSE:JNJ) - share market updates (press release) (NYSE:ABT) - September 10 at 8:02 AM
News IconDonaldson Capital Management buys $21,815,484 stake in Abbott ... - National Daily Press (NYSE:ABT) - September 10 at 8:02 AM
News IconMost Active Healthcare Stocks- Abbott Laboratories (NYSE:ABT), Skyline Medical (NASDAQ:SKLN) - Seneca Globe (NYSE:ABT) - September 9 at 3:15 PM


Abbott Laboratories (NYSE:ABT) Chart for Sunday, September, 25, 2016

Last Updated on 9/25/2016 by Staff